Previous 10 | Next 10 |
Top line results or TLR from the IMerge phase 3 trial will be out by January 2023. This is a confirmatory trial that may lead to an NDA, if successful. The CEO says he can't wait. Guess what, neither can we. For further details see: Geron: TLR Is 10 Months Away
Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in relapsed/refractory multiple myeloma is expected in mid-year. The company has multiple partnerships (including with Pfizer, GlaxoSmithKline, Janssen, Se...
GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future. Despite being a ‘Genomic Revolution’ fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better ‘...
PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...
Health Care Select Sector SPDR (NYSEARCA:XLV) has bled out $1.8B in capital outflows over the past month, leading all Select Sector SPDR ETFs according to a recent Goldman Sachs note. In addition, XLV falls in the top 10 among all exchange traded funds for outflows over the past month, w...
Price pressures are most concentrated in those sectors reporting the greatest constraints. Output consequently fell in China as well as a number of other smaller Asia-Pacific economies, and growth slowed in the US and Europe. The constraints on production caused by a lack of input...
Defensive stocks are often misunderstood. In recent years, even when they have delivered strong and steady earnings, returns have disappointed. After a period of underperformance for defensives, a broadening market can represent real opportunity. Beyond utilities, we believe that ...
Much of last week’s economic focus was on the inflation report. Inflation was indeed pretty hot year over year, but that wasn’t unexpected. With CPI printing at 5% year over year, bond yields fell. But these are small moves, and the trend for rates is still up for now. ...
Gainers: S&P Biotech Bull 3X Direxion (LABU) +21.7%.Breakwave Dry Bulk Shipping ETF (BDRY) +18.4%.Pharmaceutical & Medical Bull 3X Direxion (PILL) +14.5%.Ultra Nasdaq Biotech Proshares (BIB) +11.8%.Ultra DJ-UBS Natural Gas Proshares (BOIL) +11.6%.Losers: ...
From a consumer perspective, the consumer is actually now demanding a focus on environmental, social, governance factors. If public expectations for inflation do rise, that is going to be a change from years past. There’s going to be an opportunity to make medical progress ...
News, Short Squeeze, Breakout and More Instantly...
ProShares Ultra Nasdaq Biotechnology Company Name:
BIB Stock Symbol:
NASDAQ Market:
2024-05-19 12:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-19 23:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-31 02:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...